

## PROLIGHT SHOWCASES PSYROS™ TO GLOBAL KEY OPINION LEADERS IN CARDIOLOGY AT 2024 CARDIAC MARKERS DIALOGUE MEETING

**Prolight Diagnostics today announces its participation at the 2024 Cardiac Markers Dialogue Meeting, on 26th September and 27th September in Glasgow, UK. This prestigious event brings together key opinion leaders including leading researchers and healthcare professionals, to discuss advances in cardiac biomarker diagnostics and their implications for patient care.**

The 2024 meeting provides an invaluable platform for Prolight to showcase its single molecule counting POC platform Psyros™ and engage in dialogue with experts. It is also an opportunity to gain insight to state of the art on critical topics such as advances in biomarker research, their use in early detection of cardiac events, and the integration of new technologies in clinical practice.

"Our commitment to advancing rapid diagnosis of potential myocardial infarction at the point of care aligns perfectly with the goals of the Dialogue Meeting. We look forward to engaging with fellow professionals, sharing our technology, and fostering collaborations that can lead to improved outcomes for patients worldwide. We are honoured to sponsor this important event," said Dr Aileen McGettrick, CSO of Prolight.

The Cardiac Markers Dialogue Meeting will feature keynote speakers, panel discussions, and workshops designed to enhance understanding and application of cardiac markers in clinical practice.

For more information about the 2024 Cardiac Markers Dialogue Meeting, please visit **Cardiac Marker Dialogues – Cardiac Marker Dialogues ([cmdmeeting.org.uk](https://cmdmeeting.org.uk))**

### **For further information, please contact:**

Ulf Bladin, CEO

E-mail: [ub@prolightdx.com](mailto:ub@prolightdx.com)

Phone: +46 73 582 39 87

Company website: [www.prolightdx.com](https://www.prolightdx.com)

### **About Us**

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

## **Attachments**

**Prolight showcases Psyros™ to global key opinion leaders in cardiology at 2024 Cardiac Markers Dialogue Meeting**